Source comparison
MK-677 Long-Term IGF-1 Elevation: Study Design Comparison
Healthy elderly adults (mean age 64) 24 months 25mg oral 123 201 +63% Mild transient hyperglycaemia, water retention (resolved by week 8) Demonstrates sustained elevation without dose escalation. The gold standard for durability research Obese adults (BMI 30–4
This comparison does not assign a generated winner or score.
- Healthy elderly adults (mean age 64)
- 24 months
- 25mg oral
- 123
- 201
- +63%
- Mild transient hyperglycaemia, water retention (resolved by week 8)
- Demonstrates sustained elevation without dose escalation. The gold standard for durability research
- Obese adults (BMI 30–40)
- 8 weeks
- 178
- 289
- +62%
- Increased appetite (23% of subjects), mild insulin resistance
- Short-term validation of mechanism. Appetite effects limit long-term adherence in metabolic studies
- GH-deficient adults
- 12 months
- 67
- 142
- +112%
- Oedema (18%), transient hyperglycaemia
- Largest IGF-1 response due to low baseline. Confirms dose-response relationship holds across populations
- Young resistance-trained males (mean age 24)
- 241
- 367
- +52%
- Increased appetite, mild water retention
- Demonstrates efficacy even in populations with high baseline IGF-1. Useful for body composition research